Removal of a migrated dexamethasone implant (Ozurdex) from the anterior chamber using an intravenous cannula

BMJ Case Rep. 2021 Jul 9;14(7):e240504. doi: 10.1136/bcr-2020-240504.

Abstract

Ozurdex is a dexamethasone intravitreal implant used for the treatment of macular oedema. A rare but serious complication is the migration of the implant into the anterior chamber (AC) in eyes with absent or incomplete posterior capsules that may lead to corneal decompensation. We report the case of a 75-year-old woman who presented with a 1-day history of decreased vision in her left eye. She had a history of complicated cataract surgery and had received multiple Ozurdex implants for postoperative cystoid macular oedema in the same eye. She had significant left corneal decompensation and a mobile Ozurdex implant in the AC. We report a simple but novel surgical technique for removing an Ozurdex implant from the AC using an intravenous cannula (Venflon). This technique can also be applied to removing a fluocinolone acetonide (Iluvien) implant in similar situations.

Keywords: anterior chamber; eye; macula; retina; surgery.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anterior Chamber
  • Cannula
  • Dexamethasone / adverse effects
  • Diabetic Retinopathy*
  • Drug Implants
  • Female
  • Fluocinolone Acetonide / therapeutic use
  • Glucocorticoids / therapeutic use
  • Humans
  • Intravitreal Injections
  • Macular Edema* / drug therapy

Substances

  • Drug Implants
  • Glucocorticoids
  • Fluocinolone Acetonide
  • Dexamethasone